Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease

Plain-language summary

This study investigates the symptoms, biomarkers and mechanisms of the chronic phase of antibody-mediated LGI1 encephalitis and evaluates a remote cognitive rehabilitation program. It enrolls patients who are in the post-acute phase of the disease and have been discharged from hospital. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Intervention

Remote cognitive rehabilitation program

Start date

12/18/2023

Estimated completion

12/31/2026

Countries

Spain

Related genes

Locations

• Barcelona, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with Antibody-mediated LGI-1 encephalitis in the post-acute stage of the disease;
* Patients has been discharged from hospital (acute phase).

Exclusion Criteria:

* Inability to obtain informed consent;
* Inability to travel to the center.